SCHEMBL2779299

SCHEMBL2779299

N[C@@H](Cc1ccc(CCl)cc1)C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.69
PTGS1 P23219 3/20 0.68
ALPI P09923 1/20 0.68
PKM P14618 1/20 0.68
XIAP P98170 1/20 0.68
HIF1A Q16665 5/20 0.63
CYP3A4 P08684 3/20 0.63
ALOX15 P16050 3/20 0.63
ALDH1A1 P00352 2/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
TDP1 Q9NUW8 2/20 0.63
KDM4E B2RXH2 2/20 0.63
ABCB11 O95342 1/20 0.63
CHRM2 P08172 1/20 0.63
ADRA2A P08913 1/20 0.63
CHRM1 P11229 1/20 0.63
ACHE P22303 1/20 0.63
OPRM1 P35372 1/20 0.63
DRD3 P35462 1/20 0.63
SLC6A3 Q01959 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2779304 1.00 SLC7A5 (0.69) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL29101090 1.00 SLC7A5 (0.69) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL2310526 0.89 SLC7A5 (0.83) SLC7A5PTGS1ALPIPKMXIAP
Phenylalanine SCHEMBL7110128 0.86 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL25386492 0.84 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
Fenclonine SCHEMBL3140768 0.84 SLC7A5 (0.69) SLC7A5PTGS1ALPIPKMXIAP
Fenclonine SCHEMBL245828 0.84 SLC7A5 (0.69) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL25386493 0.84 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
Fenclonine SCHEMBL26383 0.84 SLC7A5 (0.69) SLC7A5PTGS1ALPIPKMXIAP
Fenclonine SCHEMBL26382 0.84 SLC7A5 (0.69) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197448-A1 CYCLOPEPTIBODIES AND USES THEREOF UNIVERSITY OF ROCHESTER (US) 2025-06-19 US claimed
EP-4490202-A1 CYCLOPEPTIBODIES AND USES THEREOF University of Rochester (US) 2025-01-15 EP claimed
WO-2023173084-A9 CYCLOPEPTIBODIES AND USES THEREOF UNIVERSITY OF ROCHESTER (US) 2023-12-14 WO claimed
WO-2023173084-A1 CYCLOPEPTIBODIES AND USES THEREOF UNIVERSITY OF ROCHESTER (US) 2023-09-14 WO claimed
US-12460317-B2 Genetically encoded, phage-displayed cyclic peptide library and methods of making the same THE TEXAS A&M UNIVERSITY SYSTEM (US) 2025-11-04 US disclosed
US-20250197448-A1 CYCLOPEPTIBODIES AND USES THEREOF UNIVERSITY OF ROCHESTER (US) 2025-06-19 US disclosed
EP-4490202-A1 CYCLOPEPTIBODIES AND USES THEREOF University of Rochester (US) 2025-01-15 EP disclosed
WO-2023173084-A9 CYCLOPEPTIBODIES AND USES THEREOF UNIVERSITY OF ROCHESTER (US) 2023-12-14 WO disclosed
WO-2023173084-A1 CYCLOPEPTIBODIES AND USES THEREOF UNIVERSITY OF ROCHESTER (US) 2023-09-14 WO disclosed
US-20230139680-A1 A GENETICALLY ENCODED, PHAGE-DISPLAYED CYCLIC PEPTIDE LIBRARY AND METHODS OF MAKING THE SAME THE TEXAS A&M UNIVERSITY SYSTEM (US) 2023-05-04 US disclosed
EP-3972625-A1 A GENETICALLY ENCODED, PHAGE-DISPLAYED CYCLIC PEPTIDE LIBRARY AND METHODS OF MAKING THE SAME The Texas A&M University System (US) 2022-03-30 EP disclosed
CN-113727725-A Genetically encoded phage-displayed cyclic peptide libraries and methods of making the same 得克萨斯A&M大学系统 2021-11-30 CN disclosed
US-6352839-B1 PREPARING VIRGINIAMYCINS FROM AN ENGINEERED MICROORGANISMS, HAVING THE ABILITY TO PREVENT BIOSYNTHESIS OF THE PRECURSOR ANTIBIOTIC; THE MICROORGANISM IS CULTURED IN THE PRESENCE OF A SECOND PRECURSOR AND THE STREPTOGRAMIN ANALOG IS RECOVERED AVENTIS PHARMA S.A. (FR) 2002-03-05 US disclosed
EP-0683792-B1 LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 ABBOTT LAB (US) 2001-09-26 EP disclosed
EP-0683792-A4 LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6. ABBOTT LAB (US) 1998-11-18 EP disclosed
EP-0770132-A1 STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS Aventis Pharma S.A. (FR) 1997-05-02 EP disclosed
US-5491217-A DECAPEPTIDES TAP HOLDING INC. (US) 1996-02-13 US disclosed
WO-1996001901-A1 STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS RHONE-POULENC RORER S.A. (FR) 1996-01-25 WO disclosed
EP-0683792-A1 LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 ABBOTT LABORATORIES (US) 1995-11-29 EP disclosed
WO-1994014841-A1 LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 ABBOTT LABORATORIES (US) 1994-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139680-A1 A GENETICALLY ENCODED, PHAGE-DISPLAYED CYCLIC PEPTIDE LIBRARY AND METHODS OF MAKING THE SAME QPCTL, LNPEP, QPCT SLC7A5 1345/4885PTGS1 4407/4885ALPI 3876/4885
US-20250197448-A1 CYCLOPEPTIBODIES AND USES THEREOF FCGR3B, FCGRT, FCGR2A SLC7A5 2011/4885PTGS1 1829/4885ALPI 4792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.